Mechanism of MicroRNA-375 Promoter Methylation in Promoting Ovarian Cancer Cell Malignancy.


Journal

Technology in cancer research & treatment
ISSN: 1533-0338
Titre abrégé: Technol Cancer Res Treat
Pays: United States
ID NLM: 101140941

Informations de publication

Date de publication:
Historique:
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 30 11 2021
Statut: ppublish

Résumé

Ovarian cancer (OC) ranks one of the most prevalent fatal tumors of female genital organs. Aberrant promoter methylation triggers changes of microRNA (miR)-375 in OC. Our study aimed to evaluate the mechanism of methylated miR-375 promoter region in OC cell malignancy and to seek the possible treatment for OC. miR-375 promoter methylation level in OC tissues and cells was detected. miR-375 expression in OC tissues and cell lines was compared with that in demethylated cells. Role of miR-375 in OC progression was measured. Dual-luciferase reporter gene assay was utilized to verify the targeting relationship between miR-375 and Yes-associated protein 1 (YAP1). Then, Wnt/β-catenin pathway-related protein expression was tested. Moreover, xenograft transplantation was applied to confirm the Highly methylated miR-375 was seen in OC tissues and cell lines, while its expression was decreased as the promoter methylation increased. Demethylation in OC cells brought miR-375 back to normal level, with obviously declined cell invasion, migration and viability and improved apoptosis. Additionally, miR-375 targeted YAP1 to regulate the Wnt/β-catenin pathway protein expression. Overexpressed YAP1 reversed the protein expression, promoted cell invasion, migration and viability while reduced cell apoptosis. Overexpressed miR-375 Our study demonstrated that demethylated miR-375 inhibited OC growth by targeting YAP1 and downregulating the Wnt/β-catenin pathway. This investigation may offer novel insight for OC treatment.

Identifiants

pubmed: 33928819
doi: 10.1177/1533033820980115
pmc: PMC8113360
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Biomarkers, Tumor 0
MIRN375 microRNA, human 0
MicroRNAs 0
Transcription Factors 0
YAP-Signaling Proteins 0
YAP1 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1533033820980115

Références

Int J Cancer. 2014 Sep 1;135(5):1011-8
pubmed: 24166096
Br J Nurs. 2013 Sep 12-25;22(17):S23-30
pubmed: 24067270
Postepy Hig Med Dosw (Online). 2015 Dec 02;69:1275-90
pubmed: 26671919
J Geriatr Oncol. 2016 Sep;7(5):354-61
pubmed: 27499341
Folia Histochem Cytobiol. 2015;53(2):105-19
pubmed: 26160682
Mol Med Rep. 2017 Aug;16(2):1007-1013
pubmed: 29067442
DNA Cell Biol. 2017 Nov;36(11):983-990
pubmed: 28933561
Oncogene. 2017 Jan 5;36(1):24-34
pubmed: 27270433
Eur Rev Med Pharmacol Sci. 2016 Jul;20(15):3223-9
pubmed: 27466996
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:139-152
pubmed: 28111228
Ann Oncol. 2016 Aug;27(8):1449-55
pubmed: 27037296
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3-14
pubmed: 27743768
Gynecol Oncol. 2013 Dec;131(3):772-9
pubmed: 24125749
J Clin Invest. 2017 Jan 3;127(1):137-152
pubmed: 27869648
Oncol Lett. 2017 Jun;13(6):4769-4775
pubmed: 28599478
Indian J Cancer. 2014 Mar;51 Suppl 3:e72-6
pubmed: 25818738
J Ovarian Res. 2019 Jan 22;12(1):6
pubmed: 30670062
Sci Rep. 2019 Mar 1;9(1):3197
pubmed: 30824765
Neoplasma. 2017;64(2):244-252
pubmed: 28043152
Oncol Lett. 2016 Sep;12(3):1821-1825
pubmed: 27588129
PLoS One. 2017 Sep 21;12(9):e0184439
pubmed: 28934230
Genomics. 2020 Jan;112(1):163-168
pubmed: 30189225
Endocr Relat Cancer. 2014 Mar 04;21(2):297-310
pubmed: 24389730
Int J Clin Exp Pathol. 2013 May 15;6(6):1095-102
pubmed: 23696927
Cell Death Dis. 2018 Jan 24;9(2):92
pubmed: 29367737
Genes (Basel). 2018 Jan 08;9(1):
pubmed: 29316729
PLoS One. 2014 Mar 12;9(3):e91770
pubmed: 24622501
Sci Rep. 2017 Aug 18;7(1):8760
pubmed: 28821788
Curr Opin Pharmacol. 2016 Aug;29:26-33
pubmed: 27262779
Cells. 2019 Nov 18;8(11):
pubmed: 31752117
Am J Physiol Cell Physiol. 2015 Oct 1;309(7):C444-56
pubmed: 26224579
Biochem Biophys Res Commun. 2010 Apr 9;394(3):623-7
pubmed: 20226166
Gene. 2018 Jul 1;662:28-36
pubmed: 29631007
Physiol Rev. 2014 Oct;94(4):1287-312
pubmed: 25287865
Nat Rev Clin Oncol. 2016 Apr;13(4):255-61
pubmed: 26787282
Cancer Cell. 2006 Jun;9(6):435-43
pubmed: 16766263
Sci Rep. 2017 May 4;7(1):1469
pubmed: 28473707
Int J Gynecol Cancer. 2016 Jun;26(5):851-8
pubmed: 27206217
Biochimie. 2019 Dec;167:12-24
pubmed: 31493469
Nat Rev Cancer. 2013 Apr;13(4):246-57
pubmed: 23467301

Auteurs

Junjun Shu (J)

Obstetrics and Gynecology Department, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.

Ling Xiao (L)

Obstetrics and Gynecology Department, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.

Sanhua Yan (S)

Obstetrics and Gynecology Department, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.

Boqun Fan (B)

Obstetrics and Gynecology Department, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.

Xia Zou (X)

Obstetrics and Gynecology Department, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.

Jun Yang (J)

Obstetrics and Gynecology Department, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH